$TTOO
T2 Biosystems, Inc. Stock $ttoo

$ttoo Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000162828017005155 Filed on May 08, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$956.0K	$941.0K	$1.096M
YoY Change	-3.43%	-14.14%	476.84%
Cost Of Revenue	$1.989M	$1.627M	$1.026M
YoY Change	11.68%	58.58%
Gross Profit	-$1.033M	-$686.0K	$70.00K
YoY Change	30.59%	-1080.0%	-63.16%
Gross Profit Margin	-108.05%	-72.9%	6.39%
Selling, General & Admin	$5.759M	$5.874M	$6.204M
YoY Change	-6.25%	-5.32%	38.79%
% of Gross Profit			8862.86%
Research & Development	$7.112M	$6.585M	$6.589M
YoY Change	11.67%	-0.06%	12.25%
% of Gross Profit			9412.86%
Depreciation & Amortization	$740.0K	$694.0K	$529.0K
YoY Change	37.04%	31.19%	111.6%
% of Gross Profit			755.71%
Operating Expenses	$12.87M	$12.46M	$12.79M
YoY Change	2.87%	-2.61%	23.72%
Operating Profit	-$13.90M	-$13.15M	-$12.72M
YoY Change	4.52%	3.32%	25.35%
Interest Expense	-$1.654M	-$1.637M	-$735.0K
YoY Change	105.47%	122.72%	53.13%
% of Operating Profit
Other Income/Expense, Net	$102.0K	$79.00K	$32.00K
YoY Change	64.52%	146.88%	220.0%
Pretax Income	-$15.46M	-$14.70M	-$13.43M
YoY Change	10.04%	9.46%	26.46%
Income Tax
% Of Pretax Income
Net Earnings	-$15.46M	-$14.70M	-$13.43M
YoY Change	10.04%	9.51%	26.42%
Net Earnings / Revenue	-1616.74%	-1562.49%	-1225.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$504.2K	-$481.5K	-$554.5K
COMMON SHARES
Basic Shares Outstanding	30.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.13M	$58.82M	$59.52M
YoY Change	-8.14%	-1.18%	-8.85%
Cash & Equivalents	$46.13M	$58.82M	$59.52M
Short-Term Investments
Other Short-Term Assets	$660.0K	$930.0K	$890.0K
YoY Change	17.86%	4.49%	15.58%
Inventory	$1.014M	$489.0K	$1.260M
Prepaid Expenses
Receivables	$981.0K	$409.0K	$360.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$48.79M	$60.65M	$62.03M
YoY Change	-7.07%	-2.22%	-6.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.51M	$14.47M	$12.29M
YoY Change	13.18%	17.72%	130.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$218.0K	$280.0K	$620.0K
YoY Change	-63.05%	-54.84%	-40.38%
Total Long-Term Assets	$14.99M	$15.01M	$12.91M
YoY Change	11.77%	16.25%	102.67%
TOTAL ASSETS
Total Short-Term Assets	$48.79M	$60.65M	$62.03M
Total Long-Term Assets	$14.99M	$15.01M	$12.91M
Total Assets	$63.78M	$75.66M	$74.94M
YoY Change	-3.24%	0.96%	2.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.660M	$1.161M	$1.550M
YoY Change	107.5%	-25.1%	32.48%
Accrued Expenses	$4.701M	$4.060M	$4.220M
YoY Change	4.24%	-3.79%	23.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.370M	$1.320M	$6.940M
YoY Change	-87.11%	-80.98%	2213.33%
Total Short-Term Liabilities	$10.47M	$8.913M	$14.72M
YoY Change	-40.11%	-39.45%	97.32%
LONG-TERM LIABILITIES
Long-Term Debt	$39.91M	$39.75M	$23.57M
YoY Change	65.12%	68.65%	14.47%
Other Long-Term Liabilities	$305.0K	$175.0K	$1.550M
YoY Change	-80.94%	-88.71%	24.0%
Total Long-Term Liabilities	$305.0K	$175.0K	$25.12M
YoY Change	-98.82%	-99.3%	15.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.47M	$8.913M	$14.72M
Total Long-Term Liabilities	$305.0K	$175.0K	$25.12M
Total Liabilities	$10.77M	$9.088M	$39.85M
YoY Change	-75.09%	-77.19%	36.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$233.8M	-$218.4M
YoY Change
Common Stock	$246.2M	$244.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.33M	$26.03M	$35.09M
YoY Change
Total Liabilities & Shareholders Equity	$63.78M	$75.66M	$74.94M
YoY Change	-3.24%	0.96%	2.98%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$15.46M	-$14.70M	-$13.43M
YoY Change	10.04%	9.51%	26.42%
Depreciation, Depletion And Amortization	$740.0K	$694.0K	$529.0K
YoY Change	37.04%	31.19%	111.6%
Cash From Operating Activities	-$12.22M	-$12.76M	-$11.84M
YoY Change	-5.64%	7.79%	60.16%
INVESTING ACTIVITIES
Capital Expenditures	-$880.0K	$1.594M	$2.158M
YoY Change	-12.87%	-26.14%	-247.81%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$880.0K	-$1.594M	-$2.158M
YoY Change	-12.87%	-26.14%	47.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	400.0K	-314.0K	-$149.0K
YoY Change	-91.43%	110.74%	-149.67%
NET CHANGE
Cash From Operating Activities	-12.22M	-12.76M	-$11.84M
Cash From Investing Activities	-880.0K	-1.594M	-$2.158M
Cash From Financing Activities	400.0K	-314.0K	-$149.0K
Net Change In Cash	-12.70M	-14.67M	-$14.14M
YoY Change	36.71%	3.7%	65.42%
FREE CASH FLOW
Cash From Operating Activities	-$12.22M	-$12.76M	-$11.84M
Capital Expenditures	-$880.0K	$1.594M	$2.158M
Free Cash Flow	-$11.34M	-$14.35M	-$13.99M
YoY Change	-5.03%	2.56%	135.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	409000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4908000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4060000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	884000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	915000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001492674
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30594342	shares
CY2017Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	T2 Biosystems, Inc.
CY2016Q4	ttoo	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	846000	USD
CY2017Q1	ttoo	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	724000	USD
CY2016Q1	ttoo	Proceeds From Issuance Of Common Stock And Stock Options Exercised ProceedsFromIssuanceOfCommonStockAndStockOptionsExercised	301000	USD
CY2017Q1	ttoo	Proceeds From Issuance Of Common Stock And Stock Options Exercised ProceedsFromIssuanceOfCommonStockAndStockOptionsExercised	339000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	962000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1161000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7066000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7728000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	242997000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	244391000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1264000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1128000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3887285	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5201343	shares
CY2016Q4	us-gaap	Assets Assets	89568000	USD
CY2017Q1	us-gaap	Assets Assets	75659000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	75438000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	60651000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	132000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	61000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73662000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59519000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73488000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58800000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58822000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30482712	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30594342	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30482712	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30594342	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	30000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1026000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1627000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	13819000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	14086000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	301000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	249000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	792000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	791000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2445000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2127000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	529000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	694000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2479000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1848000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M11D
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7400000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	679000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	199000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	82000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	36000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-494000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-409000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-318000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	576000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-314000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	56000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	111000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-735000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1637000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	517000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	993000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	63000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	803000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	489000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	389000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	215000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	351000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	262000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89568000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75659000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9885000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8913000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	39504000	USD
CY2017Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	39750000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-14143000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-14666000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-149000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-314000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2158000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1594000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11836000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12758000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-13426000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-14703000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	40773000	USD
CY2017Q1	us-gaap	Notes Payable NotesPayable	41066000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1269000	USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1316000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12723000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13145000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	699000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	573000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	281000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	280000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	49000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	175000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	79000	USD
CY2016Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	148000	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	639000	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6204000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5874000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1290000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1157000	USD
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1300000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1100000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	39338000	USD
CY2017Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	354000	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	370000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2158000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1594000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	820000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	931000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20655000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22196000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13589000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14468000	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	80000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	299000	USD
CY2016Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	659000	USD
CY2017Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	310000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6589000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6585000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	260000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	260000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203689000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218392000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218400000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	437000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	631000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1096000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	941000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	26030000	USD
CY2016Q1	us-gaap	Straight Line Rent StraightLineRent	60000	USD
CY2017Q1	us-gaap	Straight Line Rent StraightLineRent	53000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24218767	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30531180	shares
CY2017Q1	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid.</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases.</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</font></div></div>
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Business</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">T2 Biosystems, Inc. (the “Company”) was incorporated on April 27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;"> diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology ("T2MR") to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter ("CFU/mL"). The Company’s initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September 22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (“FDA”) for its first two products, the T2Dx Instrument (the “T2Dx”) and T2Candida Panel (“T2Candida”).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$58.8 million</font><font style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$218.4 million</font><font style="font-family:inherit;font-size:10pt;">. The future success of the Company is dependent on its ability to successfully commercialize its FDA approved products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 secondary public offering, its September 2016 private investment in public equity (“PIPE”) financing, private placements of redeemable convertible preferred stock and through debt financing arrangements. </font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Having obtained authorization from the FDA to market T2Dx and T2Candida, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. In addition, the Company expects that costs and expenses may increase as it continues the research and development of other product candidates and maintains, expands and protects its intellectual property portfolio. The Company may seek to fund its operations through public equity or private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida and other product candidates.</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management believes that its existing cash and cash equivalents at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, together with the additional remaining liquidity of up to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> available under an Equipment Lease Credit Facility (the “Credit Facility”) entered into in October 2015 to help the Company meet its capital equipment needs (Note 5), will be sufficient to allow the Company to fund its current operating plan for at least the next </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;">. Should the Company’s current operating plans not materialize as expected, and it is unable to obtain additional capital on a timely basis, the Company may be required to change its current operating plans to reduce its future expenses, which is within its control, in order to fund operations at reduced levels.</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For more information, refer to the section titled “Liquidity and Capital Resources” in Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations and the section entitled “Risk Factors” in the Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, for additional risks associated with our capital needs.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-005155-index-headers.html	Edgar Link	pending
0001628280-17-005155-index.html	Edgar Link	pending
0001628280-17-005155.txt	Edgar Link	pending
0001628280-17-005155-xbrl.zip	Edgar Link	pending
exhibit101-3312017.htm	Edgar Link	pending
exhibit102-3312017.htm	Edgar Link	pending
exhibit103-3312017.htm	Edgar Link	pending
exhibit104-3312017.htm	Edgar Link	pending
exhibit311-3312017.htm	Edgar Link	pending
exhibit312-3312017.htm	Edgar Link	pending
exhibit321-3312017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
t2-3312017x10qxdocument.htm	Edgar Link	pending
t2a02.jpg	Edgar Link	pending
ttoo-20170630.xml	Edgar Link	completed
ttoo-20170630.xsd	Edgar Link	pending
ttoo-20170630_cal.xml	Edgar Link	unprocessable
ttoo-20170630_def.xml	Edgar Link	unprocessable
ttoo-20170630_lab.xml	Edgar Link	unprocessable
ttoo-20170630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TTOO
T2 Biosystems, Inc. Stock $ttoo

2017 Q2 Form 10-Q Financial Statement

#000162828017005155 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO T2 Biosystems, Inc. Stock $ttoo

2017 Q2 Form 10-Q Financial Statement

#000162828017005155 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO
T2 Biosystems, Inc. Stock $ttoo